Analysis of the circulating myeloid-derived suppressor cells during androgen deprivation therapy for prostate cancer.
androgen antagonists
myeloid‐derived suppressor cells
prognosis
prostate‐specific antigen
prostatic neoplasms
Journal
IJU case reports
ISSN: 2577-171X
Titre abrégé: IJU Case Rep
Pays: Australia
ID NLM: 101764958
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
received:
23
04
2021
revised:
20
06
2021
accepted:
08
07
2021
entrez:
10
11
2021
pubmed:
11
11
2021
medline:
11
11
2021
Statut:
epublish
Résumé
The present study showed the involvement of immunosuppressive myeloid-derived suppressor cells during the disease progression in a 69-year-old man with a prostate cancer. The patient with metastatic PC (cT4N1M1ab) was initially treated with primary androgen deprivation therapy for 5 months and then chemotherapy with docetaxel, but he expired at the 8th month. In order to investigate whether myeloid-derived suppressor cells are implicated in the cancer exacerbation during androgen deprivation therapy, we assessed the long-term changes in peripheral blood myeloid-derived suppressor cell fractions by using flow cytometry. While prostate-specific antigen levels decreased after androgen deprivation therapy, the population of each myeloid-derived suppressor cell subsets increased during disease deterioration. Increase in myeloid-derived suppressor cells populations was correlated with prostate cancer progression.
Identifiants
pubmed: 34755058
doi: 10.1002/iju5.12351
pii: IJU512351
pmc: PMC8560438
doi:
Types de publication
Case Reports
Langues
eng
Pagination
367-370Informations de copyright
© 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
J Mol Med (Berl). 2012 Nov;90(11):1343-55
pubmed: 22660275
Nat Rev Immunol. 2021 Aug;21(8):485-498
pubmed: 33526920
Cancer Immunol Immunother. 2009 Jan;58(1):49-59
pubmed: 18446337
J Leukoc Biol. 2020 Jan;107(1):43-56
pubmed: 31721301
Cancer Immunol Res. 2020 Sep;8(9):1215-1227
pubmed: 32661092
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
Clin Cancer Res. 2015 Aug 15;21(16):3771-82
pubmed: 25967142
Cancer Res. 2007 Jan 1;67(1):425; author reply 426
pubmed: 17210725
Cancer Immunol Immunother. 2014 Nov;63(11):1177-87
pubmed: 25085000
Prostate. 2010 Mar 1;70(4):443-55
pubmed: 19902470
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Int J Mol Sci. 2020 Jul 31;21(15):
pubmed: 32751945
J Natl Compr Canc Netw. 2016 Jan;14(1):19-30
pubmed: 26733552
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938